Residency · Residency · Medical Genetics Genomics

X-Linked Inheritance and Dosage Compensation

X-Linked Recessive Inheritance

Key Features

X-linked recessive conditions predominantly affect males, who are hemizygous for pathogenic variants on their single X chromosome. The absence of male-to-male transmission is the defining pedigree feature, since fathers pass the Y chromosome, not the X, to their sons. Carrier females are typically unaffected but may have subtle manifestations due to skewed X-inactivation. All daughters of an affected male are obligate carriers. Each son of a carrier female has a 50% chance of being affected, and each daughter has a 50% chance of being a carrier. The characteristic pedigree pattern is oblique, with affected males connected through unaffected carrier females.

Major X-Linked Recessive Conditions

Duchenne and Becker muscular dystrophies are caused by variants in the DMD gene leading to dystrophin deficiency, with elevated creatine kinase as the earliest biomarker. Duchenne typically presents before age 5 with a more severe course, while Becker has later onset and milder progression. Hemophilia A (F8) and hemophilia B (F9) involve coagulation factor deficiency, with severity correlating with residual factor activity; inversions of intron 22 in the F8 gene account for approximately 45% of severe hemophilia A. G6PD deficiency causes episodic hemolytic anemia triggered by oxidative stressors and is the most common enzymopathy worldwide. X-linked agammaglobulinemia (BTK) results in absence of mature B cells with recurrent bacterial infections after waning of maternal antibodies. Hunter syndrome (IDS, mucopolysaccharidosis type II) presents with coarse facies, hepatosplenomegaly, and progressive neurodegeneration in the severe form.

X-Linked Dominant Inheritance

Key Features

In X-linked dominant conditions, both males and females are affected, though males are often more severely affected. Some X-linked dominant conditions are lethal in hemizygous males, resulting in only affected females and de novo male cases being observed. An affected father transmits the condition to all daughters and no sons, while an affected mother transmits to 50% of daughters and 50% of sons.

Major X-Linked Dominant Conditions

Rett syndrome (MECP2) almost exclusively affects females; males with MECP2 loss-of-function variants typically have severe neonatal encephalopathy or are non-viable. The syndrome is characterized by regression after 6 to 18 months of normal development, stereotypic hand movements, and seizures. Incontinentia pigmenti (IKBKG/NEMO) is lethal in most males; affected females show characteristic skin findings along Blaschko lines that progress through vesicular, verrucous, hyperpigmented, and hypopigmented stages. Aicardi syndrome, presumed X-linked dominant and male-lethal, features agenesis of the corpus callosum, infantile spasms, and chorioretinal lacunae, though no causative gene has been identified. Fragile X syndrome (FMR1), while technically X-linked, follows a unique inheritance pattern due to the repeat expansion mechanism, and premutation females are at risk for FXTAS (fragile X-associated tremor/ataxia syndrome) and primary ovarian insufficiency. The otopalatodigital spectrum disorders (FLNA) range from mild forms such as OPD type 1 to severe or lethal conditions including Melnick-Needles syndrome and frontometaphyseal dysplasia.

X-Inactivation (Lyonization)

The Lyon Hypothesis

In each somatic cell of a 46,XX female, one X chromosome is randomly inactivated early in embryonic development, approximately at days 12 to 16, when the epiblast contains roughly 100 cells. Unlike marsupials, where the paternal X is preferentially inactivated, inactivation in humans is random with respect to parental origin. Once established, the inactivation pattern is maintained through all subsequent mitotic divisions, making it clonally stable. The result is that every female is a functional mosaic of two cell populations, each expressing a different X chromosome.

XIST and the Inactivation Mechanism

XIST is a 17-kilobase long noncoding RNA transcribed from the X-inactivation center (XIC) at Xq13. The XIST RNA coats the X chromosome in cis and recruits PRC2 (Polycomb repressive complex 2) along with other silencing factors. The sequence of inactivation events proceeds from XIST coating to histone deacetylation, H3K27me3 deposition, DNA methylation, shift to late replication timing, and ultimately Barr body formation. Tsix, the antisense transcript, suppresses XIST on the active X chromosome to keep it transcriptionally active.

Genes Escaping X-Inactivation

Approximately 15 to 25% of X-linked genes escape inactivation and are expressed from both the active and inactive X chromosomes. These escape genes are disproportionately located in the pseudoautosomal regions (PAR1 and PAR2) and on the short arm of the X chromosome. SHOX is a notable escape gene; its haploinsufficiency explains the short stature in Turner syndrome (45,X), while its extra dosage contributes to tall stature in 47,XXY and 47,XXX. Escape genes may contribute to phenotypic differences between males and females and to the clinical features of sex chromosome aneuploidies. KDM6A (UTX) is another escape gene of interest: it functions as a tumor suppressor and may contribute to sex-specific differences in cancer susceptibility.

Skewed X-Inactivation

Random X-inactivation predicts a 50:50 ratio, but significant deviation occurs by chance in about 5 to 10% of women. Skewing is defined as greater than 80:20, and extreme skewing as greater than 95:5. Several mechanisms can cause skewing. Random or stochastic skewing can result from the small initial pool of cells at the time of inactivation. Secondary selection occurs when cells expressing one X chromosome have a survival advantage, as seen in X-linked immunodeficiency where cells expressing the mutant X are selected against. Primary skewing from rare XIST or XIC mutations can bias which X is inactivated. When the X chromosome has a structural abnormality, the structurally abnormal X is preferentially inactivated as a protective mechanism.

Manifesting Carriers

Mechanisms

Carrier females can manifest disease symptoms through two main mechanisms. Skewed X-inactivation that favors expression of the mutant X can cause carrier females to show disease manifestations. In some conditions, even random X-inactivation leads to symptoms in a proportion of carriers due to cell-autonomous effects that cannot be rescued by neighboring cells expressing the normal X.

Clinical Examples

Among DMD carriers, 2.5 to 19% develop cardiomyopathy, approximately 8% have muscle weakness, and creatine kinase may be elevated; cardiac surveillance is recommended for all carrier females. Hemophilia A and B carriers can have factor levels ranging from normal to below 30%, with bleeding symptoms correlating with factor activity; some carriers require treatment for surgical procedures. Fabry disease (GLA) carriers were previously considered "unaffected," but it is now recognized that over 70% of heterozygous females develop symptoms including pain, cardiac disease, and renal disease. Ornithine transcarbamylase (OTC) deficiency carriers face a risk of hyperammonemic crises, particularly during catabolic stress such as the postpartum period, illness, or high-protein diet; liver transplantation is occasionally needed. Retinitis pigmentosa (RPGR) carriers may show a tapetal reflex and pigmentary changes on fundoscopy, usually with mild visual impairment.

Bayesian Analysis for Carrier Risk

Framework

Bayesian analysis integrates family history, test results, and clinical information to calculate the posterior probability of carrier status. The prior probability is based on pedigree position; for example, the daughter of an obligate carrier has a 1/2 prior probability. The conditional probability incorporates additional evidence such as normal CK levels, unaffected sons, or negative molecular testing. The joint probability is calculated as prior times conditional, and the posterior probability equals the joint probability divided by the sum of all joint probabilities.

Common Scenarios

A common clinical scenario involves the mother of an isolated case of DMD. The question is whether she is a carrier or whether the variant arose de novo. Her prior probability of being a carrier is approximately 2/3, accounting for the 1/3 de novo rate. This prior is then modified by the number of unaffected sons, CK levels, and molecular testing results. For a sister of a male with an X-linked condition, if the mother is an obligate carrier, the sister's prior probability is 1/2, and each unaffected son she has reduces her posterior carrier risk.

Modern Molecular Testing Impact

Direct molecular testing has largely supplanted Bayesian analysis for many conditions, but Bayesian methods remain relevant when the familial variant is not identified, for estimating germline mosaicism risk, and for integrating multiple data sources. Bayesian analysis remains a core competency tested on genetics board examinations.

<image>A split pedigree diagram showing X-linked recessive (left) and X-linked dominant (right) inheritance patterns. The X-linked recessive pedigree shows affected males (filled squares) connected through carrier females (circles with dots), with no male-to-male transmission. The X-linked dominant pedigree shows an affected female transmitting to approximately half her sons and daughters, while an affected male transmits to all daughters and no sons. Below each pedigree, a Punnett square shows the gamete combinations with X chromosomes carrying the variant highlighted in red.</image>

<image>A diagram illustrating X-inactivation and manifesting carriers. A female embryo at the ~100 cell stage is shown with random X-inactivation occurring, producing a mosaic of two cell populations (blue cells expressing the maternal X, red cells expressing the paternal X). Three outcomes are shown: (1) approximately 50:50 random inactivation resulting in a typical unaffected carrier, (2) skewed inactivation (~90:10) favoring the normal X resulting in an asymptomatic carrier, and (3) skewed inactivation (~90:10) favoring the mutant X resulting in a manifesting carrier with clinical symptoms. Each outcome shows a bar graph of the X-inactivation ratio and the clinical consequence.</image>

<image>A Bayesian analysis calculation table for determining carrier risk in the mother of an isolated case of Duchenne muscular dystrophy. The table has columns for "Carrier" and "Non-carrier" hypotheses, rows for prior probability, conditional probability (incorporating two unaffected sons and a normal CK level), joint probability, and posterior probability. Each step is clearly labeled with the numerical values and the final posterior carrier risk is highlighted. A sidebar explains the 2/3 prior probability based on the Haldane model accounting for the 1/3 de novo mutation rate.</image>

Clinical Pearls

Never assume a female carrier of an X-linked condition is clinically unaffected. Manifesting carriers are common in conditions such as Fabry disease, OTC deficiency, and DMD cardiomyopathy, and carrier females warrant appropriate surveillance. The absence of male-to-male transmission is the hallmark distinguishing X-linked from autosomal dominant inheritance in a pedigree, though small family sizes can make this distinction challenging. Skewed X-inactivation testing on blood may not reflect the X-inactivation pattern in the clinically relevant tissue such as brain, muscle, or heart; tissue-specific inactivation patterns are what drive clinical significance. In a female with an X-autosome balanced translocation, the normal X is preferentially inactivated to preserve autosomal gene expression, which can unmask X-linked recessive conditions. Approximately 15 to 25% of X-linked genes escape inactivation, which explains why Turner syndrome (45,X) has a phenotype despite the fact that normal females inactivate one X. Germline mosaicism must be considered in mothers of apparently de novo X-linked conditions; even with negative carrier testing in blood, recurrence risk is approximately 7 to 15% for DMD. The ACMG recommends that carrier females of X-linked cardiac conditions, including DMD, Fabry, and Danon disease, receive cardiac surveillance including echocardiography.

References

• Lyon MF. Gene action in the X-chromosome of the mouse. Nature. 1961;190:372-373.
• Migeon BR. X-Linked Diseases: Susceptible Females. Genet Med. 2020;22(7):1156-1174.
• Viggiano E et al. X chromosome inactivation in carriers of Duchenne muscular dystrophy. Clin Genet. 2016;90(3):220-226.
• Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434:400-404.
• Germain DP. Fabry disease in females: a challenging diagnosis. J Med Genet. 2019;56(1):1-2.
• Young ID. Introduction to Risk Calculation in Genetic Counseling. 3rd ed. Oxford University Press. 2007.

Read this lecture as Markdown